ATE488236T1 - Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen - Google Patents
Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungenInfo
- Publication number
- ATE488236T1 ATE488236T1 AT05796128T AT05796128T ATE488236T1 AT E488236 T1 ATE488236 T1 AT E488236T1 AT 05796128 T AT05796128 T AT 05796128T AT 05796128 T AT05796128 T AT 05796128T AT E488236 T1 ATE488236 T1 AT E488236T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- dyslipidemia
- treatment
- lipid disorders
- sequelae
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61046604P | 2004-09-16 | 2004-09-16 | |
| PCT/US2005/032557 WO2006033891A2 (en) | 2004-09-16 | 2005-09-12 | Compounds for the treatment of dyslipidemia and other lipid disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE488236T1 true ATE488236T1 (de) | 2010-12-15 |
Family
ID=36090471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05796128T ATE488236T1 (de) | 2004-09-16 | 2005-09-12 | Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7629372B2 (de) |
| EP (1) | EP1796665B1 (de) |
| JP (1) | JP2008513458A (de) |
| CN (1) | CN101027056A (de) |
| AT (1) | ATE488236T1 (de) |
| AU (1) | AU2005287215B2 (de) |
| CA (1) | CA2581072A1 (de) |
| DE (1) | DE602005024836D1 (de) |
| WO (1) | WO2006033891A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101128441A (zh) * | 2005-03-04 | 2008-02-20 | 默克公司 | 具有抗糖尿病活性的稠合芳香化合物 |
| EP2010519B1 (de) * | 2006-04-14 | 2011-07-06 | Merck Sharp & Dohme Corp. | Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren |
| ITMI20062449A1 (it) * | 2006-12-19 | 2008-06-20 | Dipharma Spa | Forma cristallina di rabeprazolo sodico |
| JP2010526807A (ja) | 2007-05-07 | 2010-08-05 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法 |
| EP2484361B1 (de) | 2009-09-28 | 2015-11-11 | Kowa Company, Ltd. | Mittel zur reduzierung des gewichts von viszeralem fett |
| EA024873B1 (ru) | 2012-09-27 | 2016-10-31 | Кова Компани, Лтд. | Терапевтическое средство при дислипидемии |
| CA2919817C (en) | 2013-08-28 | 2021-05-25 | Kowa Company, Ltd. | Compositions comprising pemafibrate and an omega-3 fatty acid useful in the treatment of dyslipidemia |
| US10426757B2 (en) | 2014-05-29 | 2019-10-01 | Whitehead Institute For Biomedical Research | Compositions and methods for promoting intestinal stem cell and/or non-stem progenitor cell function |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2957195A (en) | 1994-07-01 | 1996-01-25 | Ligand Pharmaceuticals Incorporated | Screening for nuc inhibitors |
| CA2244831A1 (en) | 1996-02-02 | 1997-08-07 | John T. Olson | Method of treating diabetes and related disease states |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| WO1997027857A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Antidiabetic agents |
| AU721452B2 (en) | 1996-02-02 | 2000-07-06 | Merck & Co., Inc. | Antidiabetic agents |
| ATE236137T1 (de) * | 1996-02-02 | 2003-04-15 | Merck & Co Inc | Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit |
| JP2003523336A (ja) * | 2000-02-18 | 2003-08-05 | メルク エンド カムパニー インコーポレーテッド | 糖尿病及び脂質障害のためのアリールオキシ酢酸 |
| US6569879B2 (en) | 2000-02-18 | 2003-05-27 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| WO2002060434A2 (en) | 2000-10-31 | 2002-08-08 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| JP2004537525A (ja) | 2001-06-11 | 2004-12-16 | メルク エンド カムパニー インコーポレーテッド | ＰＰＡＲδアゴニストの投与による炎症性疾患の治療法 |
| WO2004011448A1 (en) * | 2002-07-25 | 2004-02-05 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
-
2005
- 2005-09-12 WO PCT/US2005/032557 patent/WO2006033891A2/en active Application Filing
- 2005-09-12 DE DE602005024836T patent/DE602005024836D1/de active Active
- 2005-09-12 CA CA002581072A patent/CA2581072A1/en not_active Abandoned
- 2005-09-12 AU AU2005287215A patent/AU2005287215B2/en not_active Ceased
- 2005-09-12 EP EP05796128A patent/EP1796665B1/de not_active Not-in-force
- 2005-09-12 US US11/662,808 patent/US7629372B2/en not_active Expired - Fee Related
- 2005-09-12 CN CNA2005800311758A patent/CN101027056A/zh active Pending
- 2005-09-12 JP JP2007532399A patent/JP2008513458A/ja active Pending
- 2005-09-12 AT AT05796128T patent/ATE488236T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005024836D1 (de) | 2010-12-30 |
| AU2005287215A1 (en) | 2006-03-30 |
| US20080039514A1 (en) | 2008-02-14 |
| EP1796665B1 (de) | 2010-11-17 |
| EP1796665A2 (de) | 2007-06-20 |
| WO2006033891A3 (en) | 2007-02-01 |
| AU2005287215B2 (en) | 2011-04-07 |
| CA2581072A1 (en) | 2006-03-30 |
| WO2006033891A2 (en) | 2006-03-30 |
| US7629372B2 (en) | 2009-12-08 |
| JP2008513458A (ja) | 2008-05-01 |
| EP1796665A4 (de) | 2009-08-12 |
| CN101027056A (zh) | 2007-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE488236T1 (de) | Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen | |
| PH12020500265A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| AU2013311573A8 (en) | Methods of treating Alzheimer's disease and pharmaceutical compositions thereof | |
| ATE390925T1 (de) | Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen | |
| CY1116754T1 (el) | Παραγωγα νιτροκατεχολης ως αναστολεις της comt | |
| ATE400564T1 (de) | Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen | |
| EA200701356A1 (ru) | Ингибиторы транспорта глицина | |
| ATE501721T1 (de) | Chinolin-derivate zur behandlung von latenter tuberkulose | |
| EA200800172A1 (ru) | 2,4-диаминопиримидины как ингибиторы aurora | |
| UA100132C2 (en) | Isoxazolo-pyridine derivatives | |
| DE60332738D1 (de) | Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen | |
| ATE447551T1 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
| ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
| EA201491321A1 (ru) | Фторметил-5,6-дигидро-4н-[1,3]оксазины | |
| SE0401342D0 (sv) | Therapeutic compounds | |
| DK1853232T3 (da) | Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse | |
| TNSN07263A1 (en) | Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them | |
| DE60315479D1 (de) | Pyrimidinamid derivate und deren verwendung | |
| CY1116234T1 (el) | Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
| CY1114760T1 (el) | Θεραπευτικη αγωγη αθηροσκληρωσης | |
| DE602005015697D1 (de) | Te zur behandlung von alzheimer-krankheit | |
| DE602005014632D1 (de) | Pyrrol- bzw. imidazolamide zur behandlung von obesitas | |
| EA200701813A1 (ru) | Новые амидозамещенные 6-фенилфенантридины | |
| ATE482707T1 (de) | 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen | |
| ATE446757T1 (de) | 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |